Evidence map›Paper›PMID 36723024›Full record

ArticleLab on a chip2023

Red blood cell rosetting enables size-based separation of specific lymphocyte subsets from blood in a microfluidic device.

Kumar Abhishek, Anto Sam Crosslee Louis Sam Titus, Mai T P Dinh, Anton Mukhamedshin, Chandra Mohan, Sean C Gifford, Sergey S Shevkoplyas

Open access · greenAbstract read
In one paragraph

Article in Lab on a chip, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kumar AbhishekDepartment of Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX 77204-5060, USA. sshevkoplyas@uh.edu.ORCID 0000-0003-3921-5749
Anto Sam Crosslee Louis Sam TitusDepartment of Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX 77204-5060, USA. sshevkoplyas@uh.edu.ORCID 0000-0002-7608-6520
Mai T P DinhDepartment of Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX 77204-5060, USA. sshevkoplyas@uh.edu.
Anton MukhamedshinDepartment of Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX 77204-5060, USA. sshevkoplyas@uh.edu.
Chandra MohanDepartment of Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX 77204-5060, USA. sshevkoplyas@uh.edu.
Sean C GiffordHalcyon Biomedical Incorporated, Friendswood, TX 77546, USA.
Sergey S ShevkoplyasDepartment of Biomedical Engineering, University of Houston, 3605 Cullen Blvd, Houston, TX 77204-5060, USA. sshevkoplyas@uh.edu.ORCID 0000-0002-8203-8365
University of Houston · USHalcyon Biomedical (United States) · US

Funding

Enabling pediatric leukapheresis with high-throughput microfluidic technologyR01HL151858 · NHLBI · UNIVERSITY OF HOUSTON · PI SHEVKOPLYAS, SERGEY S · 2020 to 2023
$1.6M
NHLBI NIH HHS R01 HL151858
6 · The paper itself

Abstract

The isolation of a specific lymphocyte subset from blood is the required first step in the manufacturing of many novel cellular immunotherapies. Microfluidic size-based separation methods are poised to significantly simplify this process because they require neither centrifugation nor magnetic or fluorescent labeling to operate. Lymphocytes can be separated from red blood cells (RBCs) and platelets as well as monocytes and granulocytes because their size differs from each of these cell types. However, further separation of a specific lymphocyte subset from other unwanted lymphocytes using size-based methods is impossible because all lymphocytes have approximately the same size and can only be distinguished by surface markers. This paper describes a new approach that made it possible for a size-based separation method to isolate a desired subset of lymphocytes by making unwanted lymphocytes as well as other blood cells artificially larger. The separation was enabled by selectively binding multiple RBCs to each unwanted cell to create 'rosettes' with an effective size significantly larger than the diameter of a typical lymphocyte. The desired lymphocytes remained unaffected by rosetting and were separated from the rosettes by passing the mixture through a microfluidic size-based separation device based on controlled incremental filtration (CIF). This new rosette-enabled size-based (RESIZE) separation approach demonstrated recovery of 80-90% for all lymphocyte subsets tested (CD3

Indexed as

ErythrocytesLymphocytesCell SeparationLab-On-A-Chip DevicesLymphocyte Subsets

Identifiers

PMID36723024
PMCPMC10050098
OpenAlexW4318754332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.